ReviewMedical oncology (Northwood, London, England)2025
Smart nanomedicines powered by artificial intelligence: a breakthrough in lung cancer diagnosis and treatment.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Ceramide signaling in non-small-cell lung cancer: from dysregulation to targeted therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- ZnO@PDA@Ag nanocomposite-mediated delivery of 9-bromonoscapine, an anticancer agent, for enhanced lung cancer therapy.Nanoscale advances · 2026Article
- Enzymatic Nanomotors Integrated with Plant Extracts: Biochemical Mechanisms, Applications, and Clinical Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Advancements in Nanomedicine for Precision Management of Lymphoma: Mechanisms, Diagnostics, and Therapeutic Strategies.International journal of nanomedicine · 2026Review
- Advanced microfluidic techniques for the preparation of solid lipid nanoparticles: Innovations and biomedical applications.International journal of pharmaceutics: X · 2025Review
- Emerging dual role of ferroptosis in lung cancer (Review).Oncology reports · 2025Review
- Artificial Intelligence-Driven Nanoarchitectonics for Smart Targeted Drug Delivery.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- 4D-printed microdevices for spatiotemporal detection of ctDNA and miRNA in pancreatic cancer: an in-depth review.Medical oncology (Northwood, London, England) · 2025Review
- Nanotechnology-Driven Drug Delivery Systems for Lung Cancer: Computational Advances and Clinical Perspectives.Thoracic cancer · 2025Review
- Smart nanoplatforms for early detection and immune modulation in lung cancer.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains one of the leading causes of cancer-related mortality worldwide, primarily due to challenges in early detection, suboptimal therapeutic efficacy, and severe adverse effects associated with conventional treatments. The convergence of nanotechnology and artificial intelligence (AI) offers transformative potential in precision oncology, enabling innovative solutions for lung cancer diagnosis and therapy. Intelligent nanomedicines facilitate targeted drug delivery, enhanced imaging, and theranostic applications, while AI-driven models harness big biomedical data to optimize nanomedicine design, functionality, and clinical application. This review explores the synergistic integration of AI and nanotechnology in lung cancer care, highlighting recent advancements, key challenges, and future directions for clinical translation. Ethical considerations, including data standardization and privacy concerns, are also addressed, providing a comprehensive roadmap to overcome current barriers and advance the adoption of AI-driven intelligent nanomedicines in precision oncology. This synthesis underscores the critical role of emerging technologies in revolutionizing lung cancer management.
Indexed as
Identifiers
40131617What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.